Clinical Trials Logo

Heart Failure, Diastolic clinical trials

View clinical trials related to Heart Failure, Diastolic.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06061549 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

MUSIC-HFpEF
Start date: August 24, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to test an experimental gene therapy in participants with heart failure with preserved ejection fraction, also known as diastolic heart failure. The main questions it aims to answer are: - safety and tolerability of the gene therapy; and - whether the gene therapy helps the heart ventricles relax during filling. Participants will undergo a one-time infusion of the gene therapy in the cardiac catheterization laboratory and then be followed for safety and effects on left-sided filling pressures while exercising. The first year will have multiple in-person visits followed by 4 years of biannual phone calls.

NCT ID: NCT06015776 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Purinergic Signaling and the Postmenopausal Heart

Start date: July 1, 2019
Phase:
Study type: Observational

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

NCT ID: NCT06009276 Recruiting - Clinical trials for Overweight and Obesity

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

Start date: August 30, 2023
Phase:
Study type: Observational

The purpose of the study is to determine associations between fitness status, bacteria in the mouth, and the blood flow to muscle. This study is trying to find out if fitness status impacts the bacteria that are present in the oral microbiome (environment in the mouth) or the ability of the body to send blood to the skeletal muscle. Participants will complete all or some of the following: - A mouth swab to assess the bacteria in their mouths. - Produce a saliva sample into a tube. - Cycle on a bike until you reach maximum effort. - Undergo blood draws - Wear a 24-hour non-invasive device that monitors blood pressure. - Undergo a test to assess blood flow to the muscles measured with an ultrasound. - Drink 70mL (1/3 of a cup) of concentrated beetroot juice once

NCT ID: NCT05989945 Recruiting - Stroke Clinical Trials

HIDRAdenitis Suppurativa and HEART Disease

Start date: August 1, 2023
Phase:
Study type: Observational

In a prospective observational cohort study (n = 250) the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and HS severity and determine whether these are prognostic markers of heart disease in patients suffering from hidradenitis suppurativa (HS).

NCT ID: NCT05887271 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction

AMEND
Start date: March 29, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Heart failure with preserved ejection fraction (HFpEF) is a common and serious complication of obesity and type 2 diabetes (T2D). HFpEF occurs when the heart muscle unable to relax efficiently to pump the blood around the body. This leads to fluid build-up, breathlessness and inability to tolerate physical exertion. People who develop HFpEF do less well because treatment options are limited. Pilot data in patients with obesity and diabetes and a small number of patients with HFpEF have shown improvements in exercise capacity and reversal of changes in the heart and blood vessels. This study will assess if this is achievable in a multi-ethnic cohort of patients with established HFpEF. A total of 102 adults will be invited and allocate by chance into two groups: either a 12-week diet or health advice on how to lose weight. The study will determine if weight loss over 12 weeks can improve heart function, symptoms and ability to exercise. Additionally, participants' views on changing their diet and how this has impacted their symptoms will be sought during the study in an optional interview. This will help guide treatments planning in the future to get maximum benefits, and to individualize support to patients from different cultural backgrounds.

NCT ID: NCT05768698 Recruiting - Clinical trials for Heart Failure, Diastolic

Assessment of Left Ventricular Filling Pressure by Applying Artificial Intelligence Algorithms to Left Atrial Speckle-tracking Echocardiography

LVEDP
Start date: July 20, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this single-center, prospective, observational study is to validate a software package based on an artificial intelligence algorithm for automated non-invasive estimation of LVFP against invasively measured ones by left and right heart catheterization; In addition, the added value of this new automated software to detect increased LVEDP > 15 mm Hg compared to the current ASE/EACVI algorithm for assessing diastolic dysfunction and longitudinal left atrial strain during the reservoir phase will be evaluated.

NCT ID: NCT05764564 Recruiting - Clinical trials for Heart Failure, Diastolic

External Body Pressure in Heart Failure With Preserved Ejection Fraction

Start date: April 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of the study is to test the impact of positive and negative body pressure on exercise capacity, symptoms, blood volume distribution and central cardiac hemodynamics in patients with heart failure and preserved ejection fraction. Aim 1 will study healthy volunteers and heart failure patients non invasively while Aim 2 will study heart failure patients invasively (intracardiac pressures).

NCT ID: NCT05752760 Recruiting - Heart Failure Clinical Trials

Pilot Study Lp299v Supplementation in Chronic Heart Failure

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to determine the impact of 12 weeks of Lp299v supplementation (20 million cfu/day vs. placebo) on exercise capacity, circulating biomarkers of cardiac remodeling, quality of life, and vascular endothelial function in humans with heart failure and reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) who have evidence of residual inflammation based on an elevated C-reactive protein level. This will be done in the setting of a randomized, double-blind, placebo-controlled trial.

NCT ID: NCT05677100 Recruiting - Heart Failure Clinical Trials

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

DRAIN-HF
Start date: August 23, 2023
Phase: N/A
Study type: Interventional

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

NCT ID: NCT05638230 Recruiting - Clinical trials for Heart Failure, Diastolic

Relative Importance of Cardiovascular Risk Factors and Echocardiographic Parameters Affecting Left Atrial Strain

RICH-LAST
Start date: August 1, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about left atrial reservoir strain in patients with heart failure with preserved ejection fraction. The main questions it aims to answer are: - Usefullness of LARS as a predictor of high HFA-PEFF diagnostic algorithm scores (≥5) - The relative importance of LARS in variables including each component of HFA-PEFF and traditional cardiovascular risk factors.